In 2020, Humira generated $19.83 billion in revenue for a 3.5 percent increase over 2019.
The three top drugs by 2020 revenue for 13 leading drugmakers:
AbbVie
- Humira — $19.83 billion
- Imbruvica — $5.31 billion
- Botox — $2.50 billion
Merck
- Keytruda — $14.38 billion
- Gardasil/Gardasil 9 — $3.94 billion
- Januvia — $3.31 billion
Bristol Myers Squibb
- Revlimid — $12.11 billion
- Eliquis — $9.17 billion
- Opdivo — $6.99 billion
Pfizer
- Prevnar 13/Prevenar 13 — $5.85 billion
- Ibrance — $5.39 billion
- Eliquis — $4.95 billion
Johnson & Johnson
- Stelara — $7.71 billion
- Darzalex — $4.19 billion
- Imbruvica — $4.13 billion
Gilead
- Biktarvy — $7.26 billion
- Genvoya — $3.34 billion
- Veklury — $2.81 billion
Amgen
- Enbrel — $5 billion
- Prolia — $2.76 billion
- Neulasta — $2.29 billion
Novartis
- Cosentyx — $4 billion
- Gilenya — $3 billion
- Entresto — $2.5 billion
Eli Lilly
- Trulicity — $5.07 billion
- Humalog — $2.63 billion
- Alimta — $2.33 billion
Sanofi
- Dupixent — $4.04 billion
- Lantus — $3.04 billion
- Influenza vaccine — $2.82 billion
AstraZeneca
- Tagrisso — $4.33 billion
- Symbicort — $2.72 billion
- Imfinzi — $2.04 billion
Novo Nordisk
- Ozempic — $3.25 billion
- Victoza — $2.87 billion
- NovoRapid/NovoLog — $2.59 billion
GlaxoSmithKline
- Triumeq — $2.96 billion
- Shingrix — $2.55 billion
- Seretide/Advair — $1.97 billion
More articles on pharmacy:
NIAID: AstraZeneca’s COVID-19 vaccine data may be outdated
Pfizer to develop more mRNA vaccines
Regeneron says its COVID-19 antibody cocktail reduces hospitalization, death risk by 70%
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
